Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letermovir Prophylaxis after Allogeneic Hematopoietic Cell Transplantation
Details
This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.
Eligibility
You can join if...
Inclusion Requirements
You can participate in this study if you satisfy the following criteria:
• Are at least 18 years of age or older
• Confirmed tested positive for CMV (either the donor or recipient) before undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT).
Exclusion Requirements
You cannot participate in this study if you have any of the following criteria:
• Any uncontrolled infection
• Have a known or suspected hypersensitivity to letermovir